Ketamine Oral Dosage Composition for Zero-Order Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral dosage forms of ketamine derivatives do not provide a zero-order release profile in the gastrointestinal tract, leading to variable absorption and potential adverse effects due to high peak plasma concentrations.
Innovation Solution
A pharmaceutical composition comprising a ketamine derivative, a controlled release polymer, and an anionic sulfate/sulfonate surfactant, formulated into a solid oral dosage form that achieves a zero-order release profile, reducing peak plasma concentrations and enhancing bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oral dosage forms are used, then the ketamine derivative is readily absorbed, but peak plasma concentrations cause adverse effects and variable absorption
Solution Approach 1:
The dosage form is segmented into multiple release stages using a two-stage dissolution medium simulation, with the controlled release polymer providing sustained release and the surfactant enhancing dissolution. This segmentation prevents sudden peak concentrations by distributing the drug release over time.
Solution Approach 2:
An anionic sulfate/sulfonate surfactant is introduced as an intermediary substance that facilitates the dissolution and release of the ketamine derivative from the controlled release polymer matrix. The surfactant acts as a mediator between the polymer matrix and the dissolution medium, enhancing zero-order release kinetics.
2Quantity of substance
If the release rate is increased to improve bioavailability, then absorption is enhanced, but peak plasma concentrations increase causing adverse effects
Solution Approach 1:
The controlled release polymer provides continuous, sustained release of the ketamine derivative over an extended period. This continuous action maintains therapeutic drug levels in the plasma without creating peak concentrations, as the release is spread uniformly over time rather than occurring in a sudden burst.
Solution Approach 2:
The release kinetics parameters are changed from immediate release to zero-order sustained release. By controlling the release rate parameter to be constant (zero-order) rather than rapid, the system achieves high bioavailability while preventing peak plasma concentrations that would cause adverse effects.
3Speed
If immediate release is used, then rapid absorption is achieved, but the duration of therapeutic effect is limited and dosing frequency increases
Solution Approach 1:
The release profile is transitioned from static immediate release to dynamic sustained release. The controlled release polymer system adapts the release rate to maintain therapeutic levels over an extended period, providing both rapid initial absorption and prolonged duration of action through controlled diffusion and dissolution kinetics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides sustained drug release, improving safety and tolerability by minimizing peak plasma concentrations and maintaining therapeutic effects over an extended period, while enhancing oral bioavailability and reducing side effects.
Implementation Method 1
Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile in two-stage dissolution medium
Implementation Method 2
an anionic sulfate/sulfonate surfactant
Data Source
AI summary
Pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions are disclosed. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile.